The Universal Flu Vaccine - Multi-Season Multi-Strain Flu Vaccine AUGUST 2020
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
The Universal
Flu Vaccine
Multi-Season
Multi-Strain
Flu Vaccine
CORPORATE PRESENTATION
AUGUST 2020
2 SAFE HARBOR STATEMENT This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction. All statements in this communication, other than those relating to historical facts, are "forward-looking statements" within the meaning of the United States Private Litigation Reform Act of 1995. You can identify forward-looking statements by terms including ‘‘anticipates,’’ ‘‘believes,’’ ‘‘could,’’ ‘‘estimates,’’ ‘‘expects,’’ ‘‘intends,’’ ‘‘may,’’ ‘‘plans,’’ ‘‘potential,’’ ‘‘predicts,’’ ‘‘projects,’’ ‘‘should,’’ ‘‘will,’’ ‘‘would,’’ and similar expressions intended to identify forward- looking statements. These forward-looking statements relate to our business and financial performance and condition, as well as our plans, strategies, objectives and expectations for our business, operations and financial performance and condition. However, these forward-looking statements are not guarantees of future performance and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, among others: the risk that drug development involves a lengthy and expensive process with uncertain outcome; BiondVax's ability to successfully develop and commercialize its vaccine; the length, progress and results of any clinical trials; the introduction of competing products; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals to commercialize BiondVax's products; the difficulty in evaluating business prospects; the adequacy of available cash resource and the ability to raise capital when needed; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; changes in the global pharmaceutical industry; changes in customers’ budgeting priorities; European Medicines Agency and other regulatory authority approvals; natural disasters; labor disputes; rising interest rates; general market, political or economic conditions in the countries in which we operate; pension and health insurance liabilities; volatility or crises In the financial market; arbitration, litigation and regulatory proceedings; and war or acts of terror. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. You should not unduly rely on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 20-F for the year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC’s website, www.sec.gov, and in the Company’s periodic filings with the SEC. Readers are urged to carefully review and consider the various disclosures made in the Company’s SEC reports, which are designed to advise interested parties of the risks and factors that may affect its business, financial condition, results of operations and prospects. These forward-looking statements speak only as of the date of this presentation, and we assume no obligation to update or revise these forward-looking statements for any reason, whether as a result of new information, future events or otherwise, except as required by law. One • For All : The Universal Flu Vaccine
3
BIONDVAX ON THE RADAR
More News: http://www.biondvax.com/press-releases/in-the-news/
One • For All : The Universal Flu Vaccine
4
A SEASONAL PROBLEM… A PANDEMIC THREAT
The Flu: A Serious Public Health Challenge
SEASONAL FLU – DESPITE ANNUAL VACCINE PRODUCTION (500 MILLION DOSES1)
Flu cases:
Severe illness: Deaths:
up to 20%2
3 – 5 million3 650,0003
or 1.5 billion
❖ At-risk Seniors: 89% of deaths & most hospitalizations4
❖ High economic burden: Over $361B in the USA4
❖ USA: Up to 80,000 deaths and 900,000 hospitalizations5
PANDEMIC FLU
❖ New pandemic strain: When?… Where?... Which?
❖ Higher morbidity & mortality worldwide
❖ Estimated cost in US $413B to $3.79T4
1 WHO: http://www.who.int/influenza_vaccines_plan/objectives/objective2/en/ and https://en.wikipedia.org/wiki/Influenza_vaccine#Uptake; 2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596521/;
3 WHO: http://www.who.int/news-room/detail/14-12-2017-up-to-650-000-people-die-of-respiratory-diseases-linked-to-seasonal-flu-each-year (varies annually); 4 White House Council of Economic Advisors
(CEA), Mitigating the Impact of Pandemic Influenza through Vaccine Innovation, September 2019.; 5CDC: www.cdc.gov/flu/about/disease/burden.htm and https://www.nytimes.com/2018/10/01/health/flu-
deaths-vaccine.html
5
CURRENT VACCINE FALLS SHORT: THE MISMATCH
The Flu Virus: Frequent and Unpredictable Mutations
Seasonal Flu Vaccine Effectiveness1
Average 40%, Elderly as low as 9%2
2004-05 10%
2005-06 21%
2006-07 52%
2007-08 37%
2008-09 41%
2009-10 56%
2010-11 60%
2011-12 47%
Why current solutions fall short… 2012-13 49%
2013-14 52%
• Past strains selection → Mismatch phenomenon 2014-15 19% 100%
2015-16 48% Protection
• Previous season’s vaccine will not necessarily 2016-17 40%
protect against next season’s flu strains 2017-18 38%
2018-19 29%
• 4-6 month production lag Measles, Rubella, Diphtheria, Tetanus, etc. 95%-99%
1 VE data: CDC, including https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm [Retrieved 29 October 2019]
2 World Health Organization: http://www.who.int/immunization/research/meetings_workshops/2a_Graham_pdvac_sept14.pdf
6
THE ELDERLY – AT RISK AND IN NEED
• ~80% of seasonal flu related death occurs in elderly1
• Seasonal vaccine effectiveness as low as 9% for elderly2
• 80% of older adults have at least one chronic condition3
• Influenza worsens outcomes of chronic illness
• Elderly flu cost in US estimated4 at $56B per year
(hospitalization, mortality, lost earnings)
NIH: “During the period from 1989 to 1997 the vaccination rate for
elderly persons ≥65 years of age in the US increased from 30 to 67%.
Despite this increase in coverage, mortality and hospitalization rates
continued to increase rather than decline as would be expected...”
International Journal of Epidemiology5 (Vol. 35, Issue 2, P352-353)
1 Vaccine journal: www.sciencedirect.com/science/article/pii/S0264410X15002315, Table 3; 2 WHO:
http://www.who.int/immunization/research/meetings_workshops/2a_Graham_pdvac_sept14.pdf
3 https://www.ncoa.org/healthy-aging/chronic-disease/; 4 Molinari et. al, The annual impact of seasonal influenza in the US, Vaccine 25
(2007) 5086–5096; 5 https://academic.oup.com/ije/article/35/2/352/694736;
7
MEETING MILESTONES & CATALYSTS
Solid Science, Phase 3 Clinical Stage, Strong IP
- Ongoing Pivotal Clinical
Technology developed Efficacy Phase 3 trial
by Prof. Ruth Arnon TASE June 2007 Nasdaq: BVXV Commercial
Head BiondVax’s SAB Delisted 2018 2015 pilot facility (Europe)
2005
Mid 90’s 2020
BiondVax 7 Successful Clinical Trials
operational • Two Phase 1/2 & Five Phase 2
• Israel, Europe, USA (NIH) .
• FDA IND / EMA SA
Co-Inventor of • 818 young adult to elderly participants
• M-001 shown to be safe and
immunogenic in all studies
One • For All : The Universal Flu Vaccine
8
M-001: A COMMON DENOMINATOR OF FLU VIRUSES
Target Common Regions: Nine common flu regions (epitopes)
connected to make one recombinant protein (M-001) produced in E.coli
BiondVax’s M-001 Key Advantages Existing vaccines
Universal: Broad coverage types A&B Strain specific
Single formulation enabling New vaccine every
HemAgglutinin (HA)
year-round vaccination year
NucleoProtein (NP)
Matrix protein (M1)
Quick, robust year-round production Long (4-6 month)
through E.coli fermentation (6-8 weeks) production cycle
Induces cellular (CMI) and enhances
Limited vaccine
humoral (HAI priming effect) immune
effectiveness
response to flu
Shelf life up to 24 months at 2-8⁰C Not applicable, since
(testing is ongoing) and 6 months at ~25⁰C new vaccine every
Now in prefilled syringes (room temperature) season
One • For All : The Universal Flu Vaccine
9
M-001: THE UNIVERSAL FLU VACCINE
M-001’s dual mode of action potentially offers multi-season and multi-strain protection
• Flu viruses are intracellular parasites
• Most of their lifecycle occurs inside our cells, thus are out of the reach of antibodies
• Our immune system mainly fights viral infection with cellular immunity via cytokines
Our immune system has 2 arms:
Cellular (CMI) Humoral (HAI)
Works inside infected cells BiondVax’s M-001 Works outside cells
Dual Mode of Action
T-cell Directly T-cell B-cell
induces priming
e.g. T-Helper, CD4, CD8 T-Cells effect Produce
Produce anti-viral enhances Antibodies
cytokines such as B-Cell
responses
IL-2 IFN-g
Current vaccines mainly induce
only flu strain-specific antibodies
One • For All : The Universal Flu Vaccine
10
ADVANCED CLINICAL DEVELOPMENT
M-001: Safe and Immunogenic in Young Adults to Elderly
• No treatment-related severe adverse events Group Day 0 Day 21 Day 42
• Adverse events were mild to moderate Treatment M-001 M-001 Seasonal or Pandemic HA
• All adverse events observed were transient Control Saline Saline vaccine to all participants
• Immunity: Cellular induced, humoral enhanced Baseline CMI HAI
Total
Phase Trial Year Population (age) Results
Participants
1/2 BVX-002 2009 Younger Adults (18-49) 63
1/2 BVX-003 2010 Older Adults (55-75) 60
M-001 was well tolerated and a cellular
2 BVX-004 2011 Younger Adults (18-49) 200 (CMI) and humoral (priming effect)
2 BVX-005 2012 Elderly (65+) 120 immune response was observed
2 BVX-006 2015 Older Adults (50-65) 36
2b BVX-007a 2015-16 EU Adults (18-60) 219
2 BVX-008b 2018 USA Adults (18-49) 120 Safe and significant T cell responses
818
3 BVX-010 2018 E. European Adults (50+) 12,463 Results expected by end of Oct. 2020
a BVX-007 was conducted in collaboration with the EU’s UNISEC consortium.
One • For All : The Universal Flu Vaccine
b BVX-008 conducted and led by NIAID/NIH. Clinical study report submitted June 2020.11
M-001: INDUCES CELL MEDIATED IMMUNITY (CMI)
Direct Evidence: CD8, CD4 T-cell Activated Cells Produce TH1 Cytokines (IFN-gamma, IL-2 & TNF-alpha)
BVX0051: CD4 & IFN-gamma in Elderly BVX0051: CD8 & IFN-gamma in Elderly
0.3 0.3 * M-001 twice Day 0 *
M-001 twice Day 0
% positive cells (Mean + SE)
% positive cells (Mean + SE)
0.25
** 0.25
M-001 twice Day 42
* * M-001 twice Day 42
0.2 0.2
0.15 * * 0.15
0.1 0.1
0.05 0.05 * P12
M-001: ENHANCES HUMORAL IMMUNITY (HAI)
Indirect Evidence: Extending T-Cell Priming Effect for Enhanced HAI Responses to Current Flu Vaccines
BVX0051: 2011/12, age 65+ YO
70
*
“M-001 can provide broadened enhanced immunity
60 TIV Twice M-001 + TIV extending even to influenza strains destined to
% Seroconversion
50
40
circulate in future years.” – Vaccine 2
30
20
70
10 In 2011 we *
0 administered M-001 60
% Seroprotection (HAI)
A/California/7/09 A/Perth/16/09 B/Brisbane/60/08
H1N1 pandemic swine flu to seniors 65+ 50
BVX003: 2009, age 55-75 YO
(BVX005)
40
80 TIV Twice M-001 + TIV
70
4 years later, 5 times 30
more seniors were
% seroconversion
60
20
50 seroprotected from a
40 new epidemic strain 10
30
(A/Swiss) that didn’t 0
20
10 exist in 2011! TIV 2011/12 M-001 & TIV 2011/12
0
A/Brisbane/59/07 A/Brisbane/10/07 B/Brisbane/60/08 * P13
PIVOTAL CLINICAL EFFICACY PHASE 3 TRIAL (EUROPE)
A pivotal, multicenter, randomized, modified double-blind, placebo-controlled phase 3 trial to
assess the safety and clinical efficacy of M-001, an influenza vaccine, administered intramuscularly
twice in older adults and the elderly (≥50 years of age)
Trial Design: Cohort 1 (4,042 enrolled & randomized Aug-Oct 2018) Professor Shai Ashkenazi, MD
Flexible Cohort 2 (8,421 enrolled & randomized July-Nov 2019)
enrollment
Day 1 Day 21 Day 202 ~12,400 participants
Experimental 1mg M-001 1mg M-001 Age 50+ (half 65+)
Safety, RT-PCR or Two flu seasons
culture on any ILI
Control Placebo Placebo (during flu season) Results by end of
October 2020 BiondVax’s Medical Director
• Dean of Medicine, Ariel University
• Former Director of Pediatrics at
• ILI symptoms active surveillance throughout both flu seasons Schneider Children’s Medical
Center of Israel
• Primary endpoints: Safety & clinical efficacy by reduction of illness rate • Former Lea and Arieh Pickel Chair
for Pediatric Research, Sackler
• Secondary endpoint: Reduced severity of influenza illness Faculty of Medicine
• Experienced clinician-researcher;
guided vaccines through clinical
and regulatory approval to market
One • For All : The Universal Flu Vaccine14
BIONDVAX’S NEW MANUFACTURING FACILITY
From Lab to Pilot Mid-Size Commercial Scale Facility
• Funding: EIB, BiondVax, and Israel’s Ministry of Economy & Industry
• Target annual capacity: Up to between 10 and 20 million doses in bulk
• Goal: Year-round GMP production & stockpile per market demand
Jerusalem BioPark
Hadassah Ein Kerem Campus
Jerusalem, Israel
One • For All : The Universal Flu Vaccine15
BIONDVAX: FIRST-IN-CLASS, BEST-IN-CLASS
Phase
Player Technology Pre- Status
I II III
clinical
BiondVax Statistically significant European Ph2b trial UNISEC
M-001: Synthetic protein B- & T-cell peptides (HA, M1,
consortium. NIAID/NIH sponsored ongoing collaboration
NP). Broad coverage, 6 completed clinical trials in adults N=13,281 Phase 2 in USA.
18 to 65+
Ongoing pivotal, clinical efficacy Phase 3 trial (Europe).
Imutex + 2016: Seek created Imutex with hVIVO
FLU-V: 4 T-cell peptides adjuvanted formulation
Challenge and immunogenicity trials N=408 2020: hVIVO acquired by Open Orphan (AIM: ORPH)
Phase 2 trials (field, challenge) positive results
M2SR (RedeeFlu): Single replication virus; Broadening Phase 2 challenge, intranasal, 2019 interim results
immunogenicity to flu sub type H3N2. ‘serum antibody response.’ Equity funding $27m,
First in human results reported 2018. Immunogenic in N=389 including $5.5m Aug 2017; $27m gov’t grants.
mice NIAID sponsored Phase 1, began 2019.
2019: Phase 1 CD8 T Cell response. Phase 2a results
OXV836: Recombinant poly-Arg NP (H1 strain) in VLP, expected 2021. Raised total €14.3m + up to €32.6m
produced in E.coli. CD8 T-cell activation
N=372 grants and equity (also towards corona vaccine
candidate, 2020).
Phase 1 interim results (2019), elicited cross reactive
Chimeric H1 targeting stalk of group 1 (H1,H2,H5) N=108 anti-stalk serum IgG antibodies. NIAID-sponsored Phase
1 in children.
H1ssF_3928: H1 HA stem + ferritin nanoparticle.
NIH infrastructure N=70 Phase 1 began 2019, results expected 2020.
Academic labs
Stem-only immunogens based on rational design; DNA
and RNA vaccines. Heterosubtypic protection in mice, Results in animals.
ferrets, primates
One • For All : The Universal Flu Vaccine
Based on publicly available information. Last updated February - July 202016
SUMMARY FINANCIAL DATA
• Lean structure with 25 employees. Manufacturing scale-up
and operating burn ~$700K/month
• Fully funded through end of ongoing Phase 3 clinical trial:
• €24M EIB non-dilutive co-funding agreement1
• Rights offering July 2019, $20M gross proceeds2
American Depository Shares ticker:
• Secondary offering Sept 2017, $10M gross proceeds
• Government of Israel support from Ministry of
Economy and Industry’s Israel Investment Center, and
BVXV
royalty-based grants from the Israel Innovation
Authority (formerly Office of the Chief Scientist)
1 European Investment Bank (EIB) €24M support for M-001 Phase 3 trials and commercial production also includes:
• Milestone based drawdowns received in 2018 and 2019
• Zero-percent fixed interest loan for five years after each of the 4 drawdowns
• Variable remuneration based on royalties of net sales
2 http://www.biondvax.com/2019/07/biondvax-announces-rights-offering-fully-subscribed-at-us20-million/17
FLU VACCINES – A LARGE AND GROWING MARKET
The Big Four Flu Vaccine 2019 Revenue Flu Vaccine Market
Seasonal Flu
o Worldwide: Up to $5.2B global market in 2018;
$0.69B6 expected to grow to $7.5B by 20241
o USA: $2.6B in 20192; ~174M doses in 2019/2010
GSK
17% o Forecasted CAGR of 6.37%1
$0.11B9 3%
Pandemic Flu
Sanofi o Swine Flu (A/H1N1) 2009 + first half of 2010 sales: $5-6B
Seqirus 51%
29%
worldwide by Novartis, GSK and Sanofi (on top of
seasonal flu vaccine sales)4
o >1B pandemic vaccines doses ordered in 200911
$1.20B8 “The United States has spent approximately $1 billion in these
2014/5: CSL bought [H5N1 flu vaccine stockpile] efforts to date.”5
Novartis’ Flu vaccine unit,
rebranded to Seqirus $2.12B7 “…part of our nation’s overall pandemic preparedness
strategy…stockpile of bulk vaccine…for influenza viruses with
2017: Acquired Protein
Sciences for $750M pandemic potential to vaccinate 26 million people immediately
after a pandemic is declared.”12
(1) https://www.researchandmarkets.com/research/5q8dvw/ (2) https://www.coherentmarketinsights.com/market-insight/us-influenza-vaccines-market-1127 (3) https://www.marketwatch.com/press-
release/united-states-influenza-vaccine-market-size-global-industry-analysis-segments-top-key-players-drivers-and-trends-to-2022-2019-02-27 (4) www.vaczine-analytics.com/ER_January_100128s.pdf (5)
http://www.who.int/immunization/sage/meetings/2013/november/SAGE_WG_H5vaccine_background_paper_16Oct2013_v4.pdf (6) https://www.gsk.com/en-gb/investors/corporate-reporting/annual-report-
2019#tab-1-4 [At exchange rate 1.28] (7) https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-06-07-30-00 [At exchange rate 1.12] (8) YE June 2019 https://medialib.csl.com/-
/media/shared/documents/results/2019-fy-analyst.pdf (9) https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2018/PDF/AstraZeneca_AR_2018.pdf, page 69. Likely less than $0.11B
in 2019, was not detailed in AZ FY19 annual report (10) https://www.cdc.gov/flu/prevent/vaccine-supply-distribution.htm (11) https://www.theglobeandmail.com/life/health-and-fitness/health/conditions/how-
vaccines-became-big-business/article572731/ (12) https://www.phe.gov/ASPRBlog/Lists/Posts/Post.aspx?ID=32218
MANAGEMENT
Tamar
Ron Babecoff Uri Ben-Or Elad Mark Joshua Phillipson
DVM, MEI Ben-Yedidia CPA, MBA BSc Engineering, MBA Hon. BSc, MBA
PhD
Founder, CSO & Clinical Trial Director of Business
CFO COO
President & CEO Leader Development & IR
• DVM (University of Liège) • Co-inventor of the universal • BA Business (College of • BSc. Engineering (Afeka Tel • Hon. BSc. (University of
• Master in Entrepreneurship & flu vaccine Administration) Aviv College of Engineering) Toronto)
Innovation (ISEMI, Swinburne) • PhD (Weizmann Institute of • MBA (Bar Ilan University) • MBA (Open University of Israel) • MBA (Ben Gurion University
• Omrix Biopharmaceuticals Ltd Science) • Principal bioprocess engineer of the Negev)
• Certified Public Accountant
(Marketing Manager) • Biotechnology General Ltd. (CPA) • Novartis (Technical Project • Accenture (Business
• Dexcel Pharma (Regional • Glycominds Ltd. (VP Manager - Process) Management Consultant)
Export Manager) Finance) • BioData Ltd. (Marketing
• Menorah Capital Markets Manager)
(Comptroller)
One • For All : The Universal Flu Vaccine19
BOARD OF DIRECTORS
Mr. Mark Germain Aentib Group (Managing Director), Pluristem (Director). Founder, director, chairman,
Chairman of the Board and/or investor in over twenty biotech companies
Ron Babecoff, DVM, MEI Omrix Pharmaceuticals Ltd (Marketing Manager), Dexcel Pharma Technologies Ltd.
Founder, President and CEO (Formerly Dexxon, Regional Export Manager)
Mr. Isaac Devash, MBA Credit Suisse First Boston (Investment Banking), Private equity and venture capital funds
Director (Founder)
Dr. Morris C. Laster, MD BioLineRx (CEO, Director), OurCrowd (Partner), Clil Medical (CEO), Vital Spark (CEO),
Director Kitov Pharmaceuticals (Co-founder, Director)
Dr. George Lowell, MD
ID Biomedical (CSO), Intellivax (Founder), Walter Reed General Hospital (Consultant)
Director
Dr. Yael Margolin, PhD
Gamida Cell Ltd. (Nasdaq: GMDA) (President, CEO, Director), Denali Ventures LLC (VP)
External Director
Mr. Samuel Moed
Bristol Myers Squibb (NYSE: BMY) (Senior Vice President, Corporate Strategy)
Director
Mr. Adi Raviv, MBA
Capacity Funding LLC (Principal)
External Director
Prof. Avner Rotman, PhD Biodar (CEO), Rodar (Founder), Israel Biotech Organization (Chairman, Steering
Director committee)
Dr. Ruth Ben Yakar, PhD
BioSight Ltd (CEO, Director), SHL Telemedicine (Director), Cellect Biotechnology (Director)
Director
One • For All : The Universal Flu Vaccine20
CAP TABLE
Nasdaq: BVXV ADS ADS Expiration
%
July 15, 2020 Outstanding Price Date
Ordinary ADS 11,520,566 95%
Options + RSUs 599,902 5% Variable Variable
Fully Diluted Shares
12,120,468 100.00%
Outstanding
• Voluntarily delisted from Tel Aviv Stock Exchange January 22, 2018. (ADS-Shares 1:40 ratio)
• Warrants issued to investors in connection with BiondVax’s IPO on Nasdaq in 2015 and traded
under symbol BVXVW expired in May 2020.
One • For All : The Universal Flu Vaccine21
IP: COMPREHENSIVE AND EXPANDING COVERAGE
• 74 Patents & 11 Pending Applications
• Covering polypeptides, polynucleotides, compositions, uses, formulations, production
• Expiration to 2035
Title International Priority &
Subject Matter Status Expiry
(updated: March 2020) Publication Assignee
Vaccine comprising 11/30/1998: Yeda Granted: USA
Peptide-Based Vaccine for
WO 00/032228 different epitopes of R&D licensed to Expired: 1, 3, 5, 12, 13, 15, 19, 20, USA: Aug 2020
Influenza
the virus BiondVax 22, 24, 25, 26, 31, 33, 35, 36
Wide–range vaccines
12/6/2005: Yeda R&D Granted: 1, 2, 3, 5, 9, 12, 13, 14, 18, Dec 2026
Improved Influenza Vaccine WO 2007/066334 – broad strain and
extended protection licensed to BiondVax 19, 20, 23, 25, 28, 31, 32, 33, 35, 36 USA: Jan 2027
Vaccines comprising Granted: 1, 2, 3, 4, 5, 6, 7, 8, 9, 11,
Aug 2028
Multimeric Multi-Epitope Influenza multiple copies of 12, 13, 15, 16, 17, 18, 19, 20, 21, 22,
WO 2009/016639 8/2/2007: BiondVax Brazil: Nov 2029
Vaccines several epitopes – 23, 24, 25, 27, 28, 29, 30, 31, 32, 33,
current product USA: Aug 2031
34, 35, 36
Multimeric Multi-Epitope Use of Multimeric as
Feb 2031
Polypeptides in improved Seasonal WO 2012/114323 a primer to BiondVax Granted: 1, 5, 36
and Pandemic Influenza Vaccines conventional vaccines USA: May 2031
Vaccine Compositions of
Production & Allowed: 1, 21, 36
Multimeric Multi-epitope Influenza WO 2015/151103 4/3/2014: BiondVax April 2035
formulation Pending: 5, 6, 10, 15, 17, 19
Polypeptides and their Production
1=Australia, 2=Austria, 3=Belgium, 4=Brazil, 5=Canada, 6=China, 7=Croatia, 8=Czech Republic, 9=Denmark, 10=Europe,
11=Finland, 12=France, 13=Germany, 14=Greece, 15=Hong Kong, 16=Hungary, 17=India, 18=Ireland, 19=Israel, 20=Italy,
21=Japan, 22=Korea, 23=Luxembourg, 24=Mexico, 25=Netherlands, 26=New Zealand, 27=Poland, 28=Portugal, 29=Romania,
30=Russia, 31=Spain, 32=Sweden, 33=Switzerland, 34=Turkey, 35=UK, 36=USA.The Universal Flu Vaccine Multi-Season Multi-Strain Flu Vaccine CONTACT INFORMATION: JOSHUA PHILLIPSON j.phillipson@biondvax.com +972-8-930-2529 www.biondvax.com
You can also read
